PRNewsWire
17 Dec 2025, 15:11 UTC · 45w ago
Verdict
Headline takes no side. We score RZLT −1.00 — strongly bearish.
−1.00strongly bearish
More negative than 99% of ticker scores this week
Which stocks this story touches
More negative than 99% of ticker scores this week
The company's lead drug candidate failed Phase 3 clinical trial endpoints, leading to a sharp stock price decline and a securities investigation.
More negative than 81% of ticker scores this week
The company is mentioned as the subject of a securities class action investigation.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Search tags
Read next
PRNewsWire · 19h ago
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
19h ago
+95.5%
Price is moving against the score
$3.95 vs $2.02 close before publication (Dec 16) · not market-adjusted
RZLT chart →
